The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark by unknown
Li et al. BMC Cancer  (2016) 16:295 
DOI 10.1186/s12885-016-2315-0RESEARCH ARTICLE Open AccessThe occurrence of non-melanoma
malignant skin lesions and non-cutaneous
squamous-cell carcinoma among
metastatic melanoma patients: an
observational cohort study in Denmark
Haojie Li1*, Lars Pedersen2, Mette Nørgaard2, Sinna P. Ulrichsen2, Sandra K. Thygesen2 and Jeanenne J. Nelson3Abstract
Background: Inhibitors of mutant BRAF are emerging as standard of care in patients with metastatic melanoma
who carry relevant oncogenic mutations. However, BRAF inhibitors are found to induce cutaneous squamous cell
carcinoma (cuSCC). Population-based background rates of cuSCC and non-cutaneous squamous cell carcinoma
(non-cuSCC) in the metastatic melanoma population may contextualize safety signals from randomized clinical trials
or the clinics. However, these background rates are lacking.
Methods: We conducted a historical cohort study to evaluate the background rates of new-onset non-melanoma
skin lesions and non-cuSCC among 2,814 metastatic malignant melanoma patients diagnosed in 1997–2010,
identified through the Danish Cancer Registry and the National Pathology Registry. Patients were excluded if they
had a history of cancer before the metastatic melanoma diagnosis, other than skin cancers. We determined the
incidence of non-melanoma malignant skin lesions and non-cuSCC that occurred post metastatic melanoma diagnosis,
censoring patients at death, emigration, or December 31, 2011 (end of study period), whichever came first.
Results: The median age at metastatic melanoma diagnosis was 64 years. Over 40 % of patients died within one year
of metastatic diagnosis and ~70 % died within 5 years. The percentages of patients with prior history or prevalent
disease at metastatic melanoma diagnosis included: 8.6 % with cuSCC or basal cell carcinoma (BCC), 3.9 % with actinic
keratosis (AK), and 0.7 % with Bowen’s disease. No patients had past or current non-cuSCC per study exclusion
criterion. The incidence of non-melanoma skin lesions during the 6 months post-metastatic melanoma diagnosis was
as follows: BCC, 1.8 % (42.5 per 1000 person-years [PY]); AK, 0.8 % (18.6 per 1000 PY); cuSCC, 0.1 % (1.7 per 1000 PY);
Bowen’s disease, 0.04 % (0.8 per 1000 PY); and keratoacanthoma (KA), 0 %. Non-cuSCC was observed in 3 patients
(0.1 %; 2.5 per 1000 PY) at 3 sites: bronchi, heart and lung.
Conclusion: CuSCC and non-cuSCC were rare events among metastatic melanoma patients.
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The incidence of cutaneous melanoma has been rising
during the last four decades in white populations
worldwide [1]. Although it is highly curable with sur-
gery if detected in its earliest stages, prognosis for
metastatic cutaneous melanoma patients has been his-
torically poor, with a median overall survival in the
range of 6–10 months. This poor survival was due to
limited treatment options and efficacy - mainly alkylat-
ing agents, dacarbazine and temozolomide, and im-
munotherapy with IL-2 and/or interferon-alpha (IFN-α)
[2]. Recently, treatment with immunotherapy or inhib-
ition of the mitogen-activated protein kinase (MAPK)
pathway has demonstrated clinical benefit by prolong-
ing OS and progression-free survival (PFS) in random-
ized trials [3–7].
However, non-melanoma skin cancers — well-
differentiated cutaneous squamous-cell carcinomas
(cuSCC) and keratoacanthomas (KA) — have devel-
oped in approximately 11 % to 30 % of patients treated
with type I BRAF inhibitors such as dabrafenib and
vemurafenib [3, 8–12]. The incidence of cuSCC in
vemurafenib-treated patients was 24 % and mostly oc-
curred early in the course of treatment, with a median
time to the first appearance of 7 to 8 weeks [8]. Ap-
proximately one third of the patients who experienced
cuSCC had more than 1 event, with a median time of
6 weeks between occurrences. Potential risk factors as-
sociated with cuSCC for those vemurafenib-treated pa-
tients have been shown to be older age (≥65 years),
prior skin cancer, and chronic sun exposure. A pro-
spective observational study of patients enrolled in the
phase I ⁄II clinical trials of dabrafenib revealed 18
cuSCCs occurred in eight out of 41 patients (20 %)
[10]. Patients who developed cuSCCs were substan-
tially older than the rest of the study population (me-
dian age 62 vs. 40 years). Most cuSCCs (77 %)
appeared between weeks 6 and 24 following com-
mencement of therapy on both sun-damaged and non-
sun-damaged skin.
It is well established that actinic keratoses (AKs) are
premalignant lesions that can progress to cuSCCs at a
rate of approximately 10 % per year [13, 14]. Similar to
AKs, KAs may also belong to a spectrum of premalig-
nant lesions that can transform into cuSCC over time
[15]. The histologic similarities of KAs and cuSCCs, in-
cluding infiltration and cytologic atypia [13, 16–19], and
the reports of KAs metastasizing also support the idea
that KAs are a type of well differentiated cuSCC [17, 20].
The background rates of incident malignant skin le-
sions among melanoma patients are lacking in the litera-
ture. Such data will help to contextualize emergent
safety signals observed in clinical trials or the clinics
among metastatic melanoma patients. We thereforeexamined the incidence rates of non-melanoma malig-
nant skin lesions and non-cuSCC in a population-based
study of metastatic melanoma patients in Denmark.
Methods
Study design
This was a historical observational cohort study among
patients diagnosed with metastatic (stage IV) melan-
oma, based on prospectively collected data obtained
from population-based medical databases in Denmark.
According to Danish legislation, purely registry-based
studies do not need permission from an ethical board.
Our study was approved by the Danish Data Protection
Agency (Jr no 2009-41-3653). Moreover, we were
granted permission to abstract information from the
medical files without obtaining informed consent by
the National Board of Health.
The Danish National Health Service provides tax-
supported health care for all inhabitants of Denmark.
The Danish Cancer Registry (DCR) established in 1943
contains records of all incident cancers diagnosed in
living patients or identified through autopsy. The 10th
revision of the International Classification of Diseases
(ICD-10) has been used to code tumors since 1978.
DCR files include information on cancer type, site,
morphology, and cancer history. It has been found to
have a high degree of completeness [21, 22] and the
proportion of morphologically verified tumors is 89 %
[23]. The National Pathology Registry (NPR), which has
been nationwide since 1997, contains data on type of
pathological specimens, procedures, pathological tests
and results, and the diagnoses assigned. Diagnoses are
coded according to the SNOMED classification. The
Danish Civil Registration System (CRS) has recorded
data on residency, vital status, and marital status for
the entire Danish population since 1968 [24]. The data
on death (yes/no) are more than 99 % complete and
very accurate [25].
Study population
We identified all patients (age ≥18 years) diagnosed with
metastatic (stage IV) melanoma from 1997 to 2010 in
Denmark. Eligible patients included those who had ini-
tial diagnoses of metastatic (stage IV) cutaneous melan-
oma during 1997 to 2010 and those who had earlier
stage melanoma at initial diagnosis who then progressed
to metastatic (stage IV) melanoma during 1997 to 2010.
Only those who had melanoma as their first primary
cancer were included. Patients were excluded if they had
a history of cancer, other than melanoma, basel-cell car-
cinoma (BCC), cuSCC, Bowen’s disease, AK and KA, be-
fore the metastatic melanoma diagnosis.
Metastatic melanoma patients were identified using
two national databases ― the DCR and the NPR, based
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ology Codes (Appendix). The DCR documents the initial
diagnoses of all primary cancers; the NPR captures a
large number of metastatic melanomas identified during
the follow-up post initial melanoma diagnosis, although
it is not 100 % complete. The index date for a patient
was defined as the date of metastatic melanoma diagnosis.
The Danish Civil Registration Number, a unique identifi-
cation number assigned to every Danish citizen at birth or
immigration, was used to link the DCR and NPR to the
CRS for obtaining data on patient demographics, medical
history, immigration, and death. All metastatic melanoma
patients were followed until death, emigration, or end of
study period, i.e., December 31, 2011.
Outcome definitions and measures
Overall survival status for these patients was described
at 3, 6, 12, 36, and 60 months after metastatic melanoma
diagnosis. Non-melanoma malignant skin lesions and
non-cutaneous squamous-cell carcinoma were identified
over the continuous intervals of 1, 2, 3, 6, 9, and 12 months
after the index date, and over the total follow-up. Events
of cuSCC, BCC, Bowen’s disease, AK, and KA were identi-
fied with SNOMED codes (Appendix), with restriction to
the non skin topology site.
Validation of metastatic melanoma diagnosis in the NPR
Medical charts were reviewed for a random sample of
65 metastatic melanoma patients, with a registration of
metastatic melanoma (including lymph node metasta-
ses) in the NPR. Of these, 40 (62 %) patients were ad-
mitted to Department of Oncology in Aarhus and 25
(38 %) patients were admitted to the Department of
Plastic Surgery in Aalborg. Medical records for one pa-
tient from Aalborg could not be located. Of the
remaining 64 patients, all had metastatic cutaneous
melanoma according to the medical records, yielding a
positive predictive value (PPV) of 100 % (95 % confi-
dence interval [CI]: 96.2-100.0).
Statistical analysis
Mean, standard deviation, median, and range were de-
rived for continuous variables, and number and propor-
tion were described for categorical variables. All patients
were followed from date of metastatic melanoma diag-
nosis until death, migration out of Denmark, or the end
of study period (i.e., December 31, 2011). Kaplan-Meier
survival curves were derived to describe time to death
over the 3, 6, 12, 36, and 60 months after metastatic
melanoma diagnosis. Patients were considered as cen-
sored if they were lost during the follow-up or if there
was no enough follow-up time allowed at the end of the
study period. Mortality rate and the CIs were calculated
using the method outlined by Simon et al. [26].We described the number and proportion (and 95 % CI)
of patients with a history or pre-existing non-melanoma
malignant skin lesions (i.e., BCC, cuSCC, Bowen’s disease,
AK and KA, eligible) prior to metastatic melanoma diag-
nosis. None of these melanoma patients had a history or
pre-existing non-cuSCC, by study design.
To be consistent with most clinical trial studies, for
the current study, the incidence analysis on non-
melanoma malignant skin lesions was first conducted
among patients regardless of whether they had a history
or pre-existing non-melanoma malignant skin lesions.
The incidence analysis was further conducted among pa-
tients who had no history or pre-existing non-melanoma
malignant skin lesions. The incidence analysis of non-
cuSCC was conducted among all eligible patients. The
sites of non-cuSCC were described. We described cumu-
lative incidence in proportion, and incidence rate in
person-year of non-melanoma malignant skin lesions (or
non-cuSCC) over the continuous intervals of 0–1, 0–2,
0–3, 0–6, 0–9, 0–12 months (i.e., 0–30, 0–60, 0–90, 0–
180, 0–270, 0–365 days), and over the total follow-up,
following metastatic melanoma diagnosis. The numer-
ator was the number of metastatic melanoma patients
with non-melanoma malignant skin lesions (or non-
cuSCC) occurring during the specified time period post
metastatic melanoma diagnosis. For the determination
of cumulative incidence, the denominator was the
number of eligible metastatic melanoma patients. For
the determination of incidence rate, the denominator
was the total person-years of eligible metastatic melan-
oma patients, with the person-year for each patient cal-
culated as the time from metastatic melanoma
diagnosis to date of the event, death, last contact, or
end of the study period, whichever occurred first. The
incidence analyses were further stratified by age at
diagnosis (18- < 65, 65- < 75, 75- < 85, and 85+ years).
All analyses were further stratified and compared be-
tween two subgroups, patients with metastatic disease at
initial diagnosis and patients diagnosed with early stage
melanoma initially who then progressed to metastatic
stage during the follow-up. All analyses were done using
SAS 9.2 software (Cary, NC, USA).
Results
During 1997–2010, 3,669 metastatic (stage IV) melan-
oma patients were identified from the DCR and NPR,
including 855 (23 %) patients with a history of cancer,
other than cutaneous melanoma, BCC, cuSCC, Bowen’s
disease, AK, and KA, before the metastatic melanoma
diagnosis (Table 1). Compared to patients with a history
of cancer, those without a history of cancer (n = 2,814)
were younger (median age = 64 vs. 69 y) at metastatic
melanoma diagnosis. A greater proportion of patients
with a history of cancer died (87.6 %) with a median
Table 1 Patient characteristics: comparison between those with
(excluded) and without (included) prior history of cancera




N % N %
Total N 855 100.0 2814 100.0
Age (y) at diagnosisb
Mean (SD) 67.9 (12.9) 63.3 (15.4)
Median (range) 69 (27–96) 64 (19–103)
Male 425 49.7 1540 54.7
Born in Denmark 836 97.8 2727 96.9
Site of metastasisb
Skin 289 33.8 1527 54.3
Soft tissue 36 4.2 166 5.9
Liver 215 25.1 115 4.1
Lung 35 4.1 89 3.2
GI Tract 38 4.4 64 2.3
Brain 35 4.1 59 2.1
Bone 16 1.9 39 1.4
Salivary gland 12 1.4 34 1.2
Mamma 10 1.2 28 1.0
Cytology, pleura 4 0.5 17 0.6
Mucous membrane 6 0.7 6 0.2
Gallbladder/Pancreas 2 0.2 5 0.2
Vulva 4 0.5 5 0.2
Unspecified or unknown 153 17.9 660 23.5
Deathb 749 87.6 2093 74.4
Time (mo) to deathb,
Median (range)
5.7 (0–156) 9.7 (0–176)
aPatients were excluded if they had a history of cancer, other than melanoma,
basal cell carcinoma, cutaneous squamous cell carcinoma, Bowen’s disease,
actinic keratoses, and keratoacanthoma, before the metastatic melanoma
diagnosis
bP-value < 0.0001 for age at diagnosis (T-test), time to death (Wilcoxon rank
sum test), number of death and site of metastasis (Chi-squared test)
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a history of cancer (74.4 %, median time to death =
9.7 months).
Of 2,814 metastatic melanoma patients who had no
history of cancer (i.e., other than cutaneous melanoma,
BCC, cuSCC, Bowen’s disease, AK and KA), 1,313
(47 %) patients were initially diagnosed with stage IV
melanoma, and 1,501 (53 %) patients were initially diag-
nosed with earlier stage melanoma and then progressed
to stage IV at a later date (Table 2). Over time from
1997 to 2010, the proportion of patients with stage IV
melanoma as the initial diagnosis decreased from 64.8 %
to 40.6 %. Of these, 2,093 (74 %) patients died during
the observation period (by December 31, 2011) and the
overall mortality rate was 289.2 (95 % CI: 277.1-301.9)
per 1000 person-years (PY). Among those who died, themedian duration from metastatic disease diagnosis to
death was 8.6 months for those diagnosed initially with
stage IV melanoma and 10.6 months for those who pro-
gressed to stage IV at a later date.
The Kaplan-Meier curve (Fig. 1) illustrates the overall
survival for patients with metastatic cutaneous melan-
oma. The overall 1-year survival was 58 % (95 % CI:
56 %-59 %) among 2,814 patients. The 1-year survival
was slightly lower among patients who were diagnosed
with stage IV melanoma initially (54 %, 95 % CI: 52 %-
57 %), compared to those who had initially early stage
melanoma and progressed to stage IV at a later date
(60 %, 95 % CI: 58 %-63 %). The 5-year survival was
26 % (95 % CI: 24 %-28 %) overall, 25 % (95 % CI: 22 %-
27 %) for patients who were diagnosed with stage IV
melanoma initially, and 27 % (95 % CI: 25 %-30 %) for
those who had initially early stage melanoma and pro-
gressed to stage IV at a later date.
Of the 2,814 metastatic melanoma patients with no
prior history of other cancers, 8.6 % (95 % CI: 7.6 %-
9.7 %) had a history or pre-existing cuSCC or BCC,
3.9 % (95 % CI: 3.2 %-4.6 %) had a history or pre-
existing AK, and less than 1 % of these patients had a
history or pre-existing Bowen’s disease or KA at meta-
static melanoma diagnosis (Table 3). Patients who had ini-
tial early stage melanoma who progressed to stage IV
disease at a later date had a higher prevalence of SCC/
BCC (10.7 %; 95 % CI: 9.2 %-12.4 %) and AK (4.9 %; 95 %
CI: 3.9 %-6.0 %) than those who had stage IV metastatic
melanoma at initial diagnosis (SCC/BCC, 6.2 %, 95 % CI:
5.0 %-7.7 %; and AK, 2.7 %, 95 % CI: 2.0 %-3.7 %).
The cumulative incidence and incidence rates (Table 4)
of non-melanoma malignant skin lesions are presented
for all metastatic melanoma patients, including those
who had a history of or pre-existing non-melanoma ma-
lignant skin lesions. Four patients died on the index
date, thus leaving 2,810 patients for the incidence ana-
lysis. During the first 6 months post diagnosis, the cu-
mulative incidence (and incidence rate) for all metastatic
melanoma patients was 0.1 % (1.7 per 1000 PY) for
cuSCC, 1.8 % (42.5 per 1000 PY) for BCC, 0.04 % (0.8
per 1000 PY) for Bowen’s disease, 0 % for KA and 0.8 %
(18.6 per 1000 PY) for AK. The incidence analyses were
then repeated among those with no history or pre-
existing non-melanoma malignant skin lesions (N =
2,496). Of those, the cumulative incidence (and inci-
dence rate) for all metastatic melanoma patients was 0 %
for cuSCC and KA, 1.0 % (22.8 per 1000 PY) for BCC,
0.04 % (0.9 per 1000 PY) for Bowen’s disease, and 0.5 %
(12.3 per 1000 PY) for AK. Of metastatic melanoma pa-
tients who had history or pre-existing skin lesion, the
cumulative incidence (and incidence rate), during the
first 6 months post diagnosis, was 0.6 % (15.5 per 1000
PY) for cuSCC, 8.3 % (212.3 per 1000 PY) for BCC, 0 %
Table 2 Characteristics for eligible metastatic melanoma patients who had no history of cancera
Overall Stage IV at initial diagnosis Progressed to stage IV
N % N % N %
Total N 2814 100.0 1313 100.0 1501 100.0
Year at diagnosisb
1997-2000 596 21.2 386 64.8 210 35.2
2001-2005 1015 36.1 438 43.2 577 56.8
2006-2010 1203 42.8 489 40.6 714 59.4
Age (y) at diagnosis
Mean (SD) 62.8 (15.4) 63.2 (14.9) 62.4 (15.9)
Median (range) 64 (19–103) 64 (21–97) 63 (19–103)
18- < 40 yrs 240 8.5 101 7.7 139 9.3
40- < 55 yrs 561 19.9 249 19.0 312 20.8
55- < 65 yrs 669 23.8 327 24.9 342 22.8
65- < 75 yrs 629 22.4 292 22.2 337 22.5
75- < 85 yrs 536 19.0 270 20.6 266 17.7
85+ yrs 179 6.4 74 5.6 105 7.0
Maleb 1540 54.7 679 51.7 861 57.4
Born in Denmark 2727 96.9 1269 96.6 1458 97.1
Site of metastasisb
Skin 1527 54.3 515 39.2 1012 67.4
Soft tissue 166 5.9 69 5.3 97 6.5
Liver 115 4.1 47 3.6 68 4.5
Lung 89 3.2 37 2.8 52 3.5
GI Tract 64 2.3 33 2.5 31 2.1
Brain 59 2.1 21 1.6 38 2.5
Bone 39 1.4 19 1.4 20 1.3
Salivary gland 34 1.2 10 0.8 24 1.6
Mamma 28 1.0 15 1.1 13 0.9
Cytology, pleura 17 0.6 8 0.6 9 0.6
Gallbladder/Pancreas 5 0.2 3 0.2 2 0.1
Vulva 5 0.2 3 0.2 2 0.1
Mucous membrane 6 0.2 4 0.3 2 0.1
Unspecified or unknown 660 23.5 529 40.3 131 8.7
Deathb 2093 74.4 1003 76.4 1090 72.6
Time (mo) to deathb,
median (range)
9.7 (0–176) 8.6 (0–176) 10.6 (0–160)
Mortality rates (95 % CI),
per 1000 person-years
289.2 (277.1 – 301.9) 303.2 (285.0 – 322.5) 277.5 (261.5 – 294.4)
aPatients were excluded if they had a history of cancer, other than melanoma, basal cell carcinoma, cutaneous squamous cell carcinoma, Bowen’s disease, actinic
keratosis and keratoacanthoma, before the metastatic melanoma diagnosis
bChi squared test P value: year at diagnosis (<0.0001), gender (0.003), site of metastasis (<0.0001) and number of death (0.02); Wilcoxon rank sum test P-value:
time to death (<0.05)
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PY) for AK. Compared with those with no history or
pre-existing skin lesion, the incidence of cuSCC, BCC
and AK were higher, although these results were based
on the small number (N = 314) of metastatic melanomapatients who had history or pre-existing skin lesion. We
observed virtually no differences in cumulative incidence
or incidence rate of non-melanoma malignant skin le-
sions between patients who were initially diagnosed with
metastatic melanoma and those who were initially
Fig. 1 Kaplan Meier overall survival curve for metastatic melanoma patients post metastatic disease diagnoses. Figure Legend: Figure 1 shows the
overall survival (in months) after onset of metastatic melanoma, presented for all patients, patients with Stage IV melanoma at initial diagnosis,
and patients who had initial earlier stage melanoma then progressed to stage IV melanoma. The numbers of patients at risk at 0, 3, 6, 12, 36, and
60 months for each of these three groups are shown in the table immediately below the survival curves
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gressed to stage IV at a later date.
Of 2,810 metastatic melanoma patients, 3 patients de-
veloped non-cuSCC post metastatic melanoma diagno-
sis. Two non-cuSCC events were identified in the heart
and the bronchi, respectively, during 30–60 days post
metastatic melanoma diagnosis. The third event was
identified in the lung during 90–180 days post meta-
static melanoma diagnosis. The cumulative incidenceTable 3 History or pre-existing non-melanoma malignant skin lesion
Outcome Overall (N = 2814) Stage IV at initial di
n % (95 % CI) n
cuSCC or BCC 243 8.6 (7.6-9.7) 82
Bowen’s disease 21 0.7 (0.5-1.1) 11
KA 19 0.7 (0.4-1.0) 9
AK 109 3.9 (3.2-4.6) 36
aAbbreviation: BCC, basal cell carcinoma; cuSCC, cutaneous squamous cell carcinomwas 0.1 % at 6 months after the index date, correspond-
ing to an incidence rate of 2.5 per 1000 PY (Table 5).
We further evaluated the cumulative incidence and in-
cidence rates of BCC and AK among metastatic melan-
oma patients by age at metastatic melanoma diagnosis
(Table 6). Incidence rates of BCC and AK were the low-
est among the youngest patients between 18–65 years at
metastatic melanoma diagnosis. The incidence rates of
BCC (but not AK) increased with age at metastatics prior to metastatic melanoma diagnosisa
agnosis (N = 1313) Progressed to stage IV (N = 1501)
% (95 % CI) n % (95 % CI)
6.2 (5.0-7.7) 161 10.7 (9.2-12.4)
0.8 (0.4-1.4) 10 0.7 (0.3-1.2)
0.7 (0.3-1.2) 10 0.7 (0.3-1.2)
2.7 (2.0-3.7) 73 4.9 (3.9-6.0)
a; AK, actinic keratosis; and KA, keratoacanthoma
Table 4 Cumulative incidence and incidence rate of non-melanoma malignant skin lesions among patients with metastatic melanomaa
Outcome Event, n Cumulative Incidenceb (95 % CI) Incidence Rateb (95 % CI)
Among all patients (N = 2810 c, regardless of whether they had a history or pre-existing skin lesion)
CuSCC
Within 30 d after the index date 0 – –
Within 60 d after the index date 1 0.04 (0.004-0.2) 2.3 (0.3-16.2)
Within 90 d after the index date 2 0.1 (0.02-0.2) 3.1 (0.8-12.5)
Within 180 d after the index date 2 0.1 (0.02-0.2) 1.7 (0.4-6.7)
Within 270 d after the index date 4 0.1 (0.05-0.3) 2.4 (0.9-6.4)
Within 365 d after the index date 7 0.2 (0.1-0.5) 3.3 (1.6-7.0)
Ever post index date 26 0.9 (0.6-1.3) 3.7 (2.5-5.4)
BCC
Within 30 d after the index date 15 0.5 (0.3-0.9) 66.7 (40.2-110.6)
Within 60 d after the index date 26 0.9 (0.6-1.3) 59.6 (40.5-87.5)
Within 90 d after the index date 30 1.1 (0.7-1.5) 47.1 (33.0-67.4)
Within 180 d after the index date 50 1.8 (1.3-2.3) 42.5 (32.2-56.1)
Within 270 d after the index date 59 2.1 (1.6 - 2.7) 36.0 (27.9- 46.4)
Within 365 d after the index date 68 2.4 (1.9 - 3.0) 32.9 (25.9- 41.7)
Ever post index date 140 5.0 (4.2 - 5.8) 21.0 (17.8- 24.8)
Bowen’s disease
Within 30 d after the index date 0 – –
Within 60 d after the index date 0 – –
Within 90 d after the index date 0 – –
Within 180 d after the index date 1 0.04 (0.004-0.2) 0.8 (0.1-6.0)
Within 270 d after the index date 3 0.1 (0.03-0.3) 1.8 (0.6-5.6)
Within 365 d after the index date 3 0.1 (0.03-0.3) 1.4 (0.5-4.4)
Ever post index date 9 0.3 (0.2-0.6) 1.3 (0.7-2.4)
KA
Within 30 d after the index date 0 – –
Within 60 d after the index date 0 – –
Within 90 d after the index date 0 – –
Within 180 d after the index date 0 – –
Within 270 d after the index date 1 0.04 (0.004-0.2) 0.6 (0.1-4.3)
Within 365 d after the index date 3 0.1 (0.03-0.3) 1.4 (0.5-4.4)
Ever post index date 10 0.4 (0.2-0.6) 1.4 (0.8-2.6)
AK
Within 30 d after the index date 7 0.2 (0.1-0.5) 31.1 (14.8-65.2)
Within 60 d after the index date 13 0.5 (0.3-0.8) 29.7 (17.2-51.1)
Within 90 d after the index date 17 0.6 (0.4-0.9) 26.6 (16.5-42.8)
Within 180 d after the index date 22 0.8 (0.5-1.2) 18.6 (12.2-28.2)
Within 270 d after the index date 33 1.2 (0.8-1.6) 20.0 (14.2-28.1)
Within 365 d after the index date 41 1.5 (1.1-2.0) 19.6 (14.4-26.6)
Ever post index date 91 3.2 (2.6-3.9) 13.3 (10.8-16.3)
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Table 4 Cumulative incidence and incidence rate of non-melanoma malignant skin lesions among patients with metastatic melanomaa
(Continued)
Among patients who had no history or pre-existing skin lesion (N = 2496)
cuSCC
Within 30 d after the index date 0 – –
Within 60 d after the index date 0 – –
Within 90 d after the index date 0 – –
Within 180 d after the index date 0 – –
Within 270 d after the index date 1 0.04 (0.004-0.2) 0.7 (0.1-4.8)
Within 365 d after the index date 3 0.1 (0.03-0.3) 1.6 (0.5-4.9)
Ever post index date 17 0.7 (0.4-1.1) 2.7 (1.7-4.3)
BCC
Within 30 d after the index date 10 0.4 (0.2-0.7) 49.9 (26.9-92.8)
Within 60 d after the index date 14 0.6 (0.3-0.9) 36.0 (21.3-60.7)
Within 90 d after the index date 15 0.6 (0.4-1.0) 26.4 (15.9-43.8)
Within 180 d after the index date 24 1.0 (0.6-1.4) 22.8 (15.3-34.0)
Within 270 d after the index date 27 1.1 (0.7-1.5) 18.3 (12.6-26.7)
Within 365 d after the index date 30 1.2 (0.8-1.7) 16.1 (11.3-23.1)
Ever post index date 77 3.1 (2.5-3.8) 12.5 (10.0-15.7)
Bowen’s disease
Within 30 d after the index date 0 – –
Within 60 d after the index date 0 – –
Within 90 d after the index date 0 – –
Within 180 d after the index date 1 0.04 (0.004-0.2) 0.9 (0.1-6.7)
Within 270 d after the index date 1 0.04 (0.004-0.2) 0.7 (0.01-4.8)
Within 365 d after the index date 1 0.04 (0.004-0.2) 0.5 (0.1-3.8)
Ever post index date 5 0.2 (0.1-0.4) 0.8 (0.3-1.9)
KA
Within 30 d after the index date 0 – –
Within 60 d after the index date 0 – –
Within 90 d after the index date 0 – –
Within 180 d after the index date 0 – –
Within 270 d after the index date 0 – –
Within 365 d after the index date 1 0.04 (0.004-0.2) 0.5 (0.1-3.8)
Ever post index date 6 0.2 (0.1-0.5) 0.9 (0.4-2.1)
AK
Within 30 d after the index date 4 0.2 (0.1-0.4) 19.9 (7.5-53.2)
Within 60 d after the index date 8 0.3 (0.2-0.6) 20.5 (10.3-41.0)
Within 90 d after the index date 10 0.4 (0.2-0.7) 17.6 (9.5-32.6)
Within 180 d after the index date 13 0.5 (0.3-0.9) 12.3 (7.2- 21.2)
Within 270 d after the index date 19 0.8 (0.5-1.2) 12.9 (8.2-20.2)
Within 365 d after the index date 23 0.9 (0.6-1.4) 12.3 (8.2-18.5)
Ever post index date 53 2.1 (1.6-2.7) 8.5 (6.5-11.1)
aAbbreviation: BCC, basal cell carcinoma; cuSCC, cutaneous squamous cell carcinoma; AK, actinic keratosis; and KA, keratoacanthoma
bThe incidence analysis was conducted among 2810 patients, because 4 patients died on the index date and were excluded
cCumulative incidence, %; incidence rate, per 1000 person-years
Li et al. BMC Cancer  (2016) 16:295 Page 8 of 11
Table 5 Cumulative incidence and incidence rate of non-cuSCC among patients with metastatic melanomaa
Outcome Event, n Cumulative Incidenceb (95 % CI) Incidence Rateb (95 % CI)
Within 30 d after the index date 0 – –
Within 60 d after the index date 2 0.1 (0.02-0.2) 4.6 (1.1-18.2)
Within 90 d after the index date 2 0.1 (0.02-0.2) 3.1 (0.8-12.5)
Within 180 d after the index date 3 0.1 (0.03-0.3) 2.5 (0.8-7.8)
Within 270 d after the index date 3 0.1 (0.03-0.3) 1.8 (0.6-5.6)
Within 365 d after the index date 3 0.1 (0.03-0.3) 1.4 (0.5-4.4)
Ever post index date 3 0.1 (0.03-0.3) 0.4 (0.1-1.3)
aAbbreviation: non-cuSCC, non-cutaneous squamous cell carcinoma. The incidence analysis was conducted among 2810 patients, because 4 patients died on the
index date and were excluded
bCumulative incidence, %; incidence rate, per 1000 person-years
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The age-stratified analyses were not possible for cuSCC,
Bowen’s disease, KA, and non-cuSCC because the num-
bers of these events were too small.
Discussion
This study provides population-based background rates
of non-melanoma malignant skin lesions and non-
cuSCC among over 2,800 metastatic melanoma patients
in Denmark. The Danish national registries are unique
resources for studying non-melanoma malignant skin le-
sions, as these are not generally captured in most cancer
registries elsewhere.
The uniformly organized Danish healthcare system
allows a truly population-based design. The DCR is
population-based with mandatory notification of all in-
cident cancers by hospitals, general practitioners and
practicing specialists, and has a high degree of com-
pleteness. NPR, additionally, captures a large number of
metastatic melanomas identified during the follow-up post
initial diagnosis. Utilizing both national databases in
Denmark allowed us to include not only metastatic
melanoma patients with initial diagnoses of metastatic
disease, but also those who had earlier stage melan-
oma initially then progressed to metastatic cutaneous
melanoma. Compared with most randomized clinical
trials, the results obtained from this study are rela-
tively robust, given this sample size, and the meta-
static melanoma patients included in this study
should be fairly representative of those patients in the
clinics, as only minor inclusion and exclusion criteria
were applied.
Furthermore, the data quality of DCR and NPR is
high [21–23]. Although the definition of diagnostic cri-
teria or sensitivity of the diagnostic tools may have
changed over time, which may explain the decrease in
the proportion of patients with initial metastatic melan-
oma diagnosis over time, the validity measured by theproportion of morphologically verified tumors in DCR
has been found to be 89 % [21], a very high proportion
internationally [27]. Results from our validation of
metastatic melanoma diagnosis in the NPR presented a
nearly perfect positive predictive value. Therefore, we
expect selection bias to be minimal. With the ability to
link the DCR and the NPR to the CRS, which contains
daily updated vital status of the entire Danish popula-
tion, we had virtually no loss of follow-up for these pa-
tients. These national health registries in Denmark have
been widely used in epidemiological studies [28]. Stand-
ard data quality checks are routinely performed and
missing data and loss to follow-up are relatively minor
issues for these national health registries.
This study has limitations. The completeness of the
NPR is not known. Lesions that were not histological
verified and were not reported to the cancer registry
may have been missed, and therefore the incidence
rates of non-melanoma skin lesions may be underesti-
mated. Nonetheless, the NPR in Denmark contains all
histological examinations, including those from office-
based treatment facilities. Thus, our research captured
most lesions with histological confirmation. An article
published in 2010 by Birch-Johansen F et al. [29]
showed the BCC and SCC incidence rates for Denmark
in the period 1978–2007, using data from both DCR
and NPR. The incidence rates reported in this paper
were among the highest incidence rates ever found in a
European country. The authors acknowledged that the
two registries are not 100 % complete in capturing
BCC/SCC, but suggest that the high rates may partially
be due to a more complete registration of SCC and es-
pecially BCC in these registries compared to registries
in other European countries.
We had limited statistical precision for several rare
study outcomes, especially cuSCC, Bowen’s disease, KA,
and non-cuSCC. This must be taken into consideration
when interpreting the estimates. The results from this
Table 6 Incidence rate of BCC and AK by age at metastatic melanoma diagnosisa
Outcome 18– < 65 y 65– < 75 y 75- < 85 y 85+ y
Nb Rate (95 % CI) N Rate (95 % CI) N Rate (95 % CI) N Rate (95 % CI)
Among all patients (n = 2810 c, regardless of whether they had a history or pre-existing skin lesion)
BCC
Within 30 d after the index date 7 59.4 (28.3-124.5) 2 39.5 (9.9-158.1) 2 46.8 (11.7-187.1) 4 291.2 (109.3-775.9)
Within 60 d after the index date 11 47.9 (26.5-86.5) 3 30.5 (9.8-94.6) 8 97.3 (48.6-194.5) 4 151.9 (57.0-404.8)
Within 90 d after the index date 11 32.8 (18.1-59.3) 6 41.8 (18.8-93.1) 8 66.8 (33.4-133.5) 5 131.8 (54.8-316.6)
Within 180 d after the index date 17 27.2 (16.9-43.8) 13 49.1 (28.5-84.5) 12 55.0 (31.2-96.8) 8 118.1 (59.0-236.1)
Within 270 d after the index date 19 21.7 (13.8-34.0) 16 43.4 (26.6-70.9) 16 52.6 (32.2-85.9) 8 87.3 (43.7-174.6)
Within 365 d after the index date 21 18.9 (12.4-29.1) 20 43.3 (27.9-67.1) 19 49.4 (31.5-77.4) 8 71.0 (35.5- 142.0)
Ever post index date 52 13.2 (10.0-17.3) 36 26.4 (19.1-36.6) 36 32.3 (23.3-44.8) 16 69.8 (42.7-113. 9)
AK
Within 30 d after the index date 2 16.9 (4.2-67.6) 3 59.4 (19.1-184.0) 1 23.4 (3.3-165.9) 1 72.5 (10.2-515.0)
Within 60 d after the index date 2 8.7 (2.2-34.7) 5 51.0 (21.2-122.4) 4 48.4 (18.2-129.0) 2 75.3 (18.8-301.3)
Within 90 d after the index date 3 8.9 (2.9-27.6) 6 41.9 (18.8-93.2) 6 49.8 (22.4-110.9) 2 52.1 (13.0-208.3)
Within 180 d after the index date 3 4.8 (1.5-14.8) 10 37.7 (20.3-70.1) 6 27.3 (12.3-60.7) 3 43.3 (14.0-134.4)
Within 270 d after the index date 4 4.5 (1.7-12.1) 13 35.2 (20.4-60.5) 11 35.8 (19.8-64.7) 5 53.5 (22.3-128.5)
Within 365 d after the index date 6 5.4 (2.4-11.9) 16 34.4 (21.1-56.1) 14 35.9 (21.3-60.6) 5 43.5 (18.1-104.5)
Ever post index date 27 6.7 (4.6-9.7) 33 23.6 (16.8-33.3) 22 19.2 (12.6-29.2) 9 36.3 (18.9-69.7)
Among patients, who had no history or pre-existing skin lesion (n = 2496)
BCC
Within 30 d after the index date 4 36.0 (13.5-96.0) 2 45.5 (11.4-181.8) 2 56.9 (14.2-227.5) 2 198.0 (49.5-791.8)
Within 60 d after the index date 6 27.7 (12.5-61.7) 2 23.4 (5.8-93.4) 4 58.8 (22.1-156.8) 2 102.9 (25.7-411.6)
Within 90 d after the index date 6 19.0 (8.5-42.3) 3 24.0 (7.7-74.4) 4 40.2 (15.1-107.2) 2 71.4 (17.9-285.6)
Within 180 d after the index date 9 15.3 (8.0-29.4) 7 30.2 (14.4-63.3) 6 32.8 (14.8-73.1) 2 39.8 (10.0- 159.3)
Within 270 d after the index date 9 10.9 (5.7-21.0) 9 27.8 (14.5-53.5) 7 27.4 (13.1-57.5) 2 29.4 (7.3-117.4)
Within 365 d after the index date 11 10.5 (5.8-19.0) 9 22.1 (11.5-42.5) 8 24.6 (12.3-49.3) 2 23.8 (6.0-95.1)
Ever post index date 36 9.6 (6.9-13.3) 19 15.5 (9.9-24.3) 17 17.4 (10.8-28.0) 5 28.0 (11.7-67.4)
AK
Within 30 d after the index date 2 18.0 (4.5-71.9) 2 45.5 (11.4-181.9) 0 – 0 –
Within 60 d after the index date 2 9.2 (2.3-36.9) 3 35.1 (11.3-108.8) 3 44.0 (14.2-136.4) 0
Within 90 d after the index date 2 6.3 (1.6-25.3) 3 24.0 (7.7-74.4) 5 50.2 (20.9-120.7) 0 –
Within 180 d after the index date 2 3.4 (0.8-13.6) 5 21.6 (9.0-51.9) 5 27.4 (11.4-65.7) 1 19.6 (2.8-139.4)
Within 270 d after the index date 3 3.6 (1.2- 11.2) 7 21.6 (10.3-45.4) 8 31.3 (15.6-62.6) 1 14.5 (2.0-103.1)
Within 365 d after the index date 5 4.8 (2.0-11.4) 8 19.6 (9.8-39.2) 9 27.7 (14.4-53.2) 1 11.8 (1.7- 83.7)
Ever post index date 18 4.7 (3.0-7.4) 21 17.0 (11.1-26.1) 11 11.9 (6.1-20.0) 3 16.2 (5.2-50.3)
aAbbreviation: BCC, basal cell carcinoma; AK, actinic keratosis. Incidence rate, per 1000 person-years
bNumber of events
cThe analysis was conducted among 2810 patients, because 4 patients died on the index date and were excluded
Li et al. BMC Cancer  (2016) 16:295 Page 10 of 11study may not be directly generalized to a different
country, region, or ethnic group.
Conclusion
In conclusion, our results suggest that metastatic mel-
anoma patients may further develop non-melanoma
skin lesions and non-cuSCC; however, the incidence is
low. Among the tumor types studied in this Danishcohort, BCC was more common, followed by AK,
cuSCC, and non-cuSCC. Bowen’s disease and KA were
the most rare. These background rates provide
population-based context for contextualizing safety sig-
nals from the randomized clinical trials. Furthermore,
these results may inform physicians and patients when
similar events are observed in the clinics among meta-
static melanoma patients.
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Codes for Non-melanoma Malignant Skin Lesions and Non-
cutaneous Squamous-cell Carcinomas




M87206, M87209, M87216, M87219,
M87306, M87406, M87409, M87416,
M87436, M87456, M874A6, M874A9,
M87606, M87609
DC43
SCC M80513, M80523, M80703, M80713
M80743 M80753 M80763
NAa
BCC M80903, M80913, M80923, M80933,
M80943, M80953
NA
Bowen’s disease M80812 NA
KA M72860 NA
AK M72850 NA
Non-cuSCC M80513, M80523, M80703, M80713
M80743 M80753 M80763
NA
aNA, not available or not relevantAbbreviations
AE: adverse event; AJCC: American Joint Committee on Cancer; AK: actinic
keratosis; CRS: the Danish Civil Registration System; BCC: basal-cell carcinoma;
cuSCC: cutaneous squamous-cell carcinomas; DCR: the Danish Cancer
Registry; ICD: International classification of diseases; KA: keratoacanthoma;
MAPK: mitogen-activated protein kinase; Non-cuSCC: non-cutaneous
squamous-cell carcinomas; NPR: the National Pathology Registry; OS: overall
survival; PFS: progression-free survival; PPV: positive predictive value;
SAS: Statistical Analysis Software.
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